DEPLOYDatabase

Company

Asensus Surgical

Asensus Surgical was a Durham, NC-based surgical robotics company that developed the Senhance Surgical System, a digital laparoscopic platform that received…

Track Asensus Surgical
Founded
2006
HQ
Durham, NC
Status
acquired by Karl Storz (Aug 2024; ~$95M; delisted)

Models

1

Overview

Asensus Surgical was a Durham, NC-based surgical robotics company that developed the Senhance Surgical System, a digital laparoscopic platform that received FDA 510(k) clearance. The company also developed the Luna surgical robot platform. Asensus was acquired by KARL STORZ in 2024 for 35 cents per share, which retired the Senhance platform, discontinued Luna development, and sunset the Asensus brand to create a surgical robotics hub for Performance-Guided Surgery.

Verified record

Verified deployments
None on file
Active incidents
2 incidents on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Key facts

Product

Senhance Surgical System (FDA 510(k) cleared)

Acquisition

Karl Storz, closed Aug 22 2024, $0.35/sh ~$95M; delisted.

Former name

TransEnterix

Luna platform

Discontinued after KARL STORZ acquisition

Data & sources

Press releases

1

News coverage

1

Web sources

2

4 sources backing this record.View all →

Models (1)

View all models →

Current platform

Senhance

Asensus Surgical, formerly TransEnterix and based in Durham, North Carolina, was a public company on the NYSE American as ASXC that made the Senhance multi-port laparoscopic robotic system, FDA-cleared via 510(k) in October 2017 with subsequent instrument and indication clearances, making Senhance a genuinely cleared if relatively low-volume commercial product. The headline current-state fact is that Karl Storz acquired the company, closing on August 22, 2024 at $0.35 per share for about $95 million, a roughly 67 percent premium, with the stock ceasing to trade on the NYSE American at close, leaving Asensus a private Karl Storz subsidiary; this is the canonical example of a large medtech company absorbing a struggling robotics startup for a fraction of its historic enterprise value. The registry records Senhance at commercial maturity with an active lifecycle, since it remains a cleared product line continuing under Karl Storz, while the company status is recorded as acquired. The company's next-generation LUNA system, unveiled in February 2023 with claimed real-time clinical intelligence and cloud machine learning, was not FDA-submitted, not cleared, and not for sale as of the August 2024 close, so LUNA is recorded at research maturity, with a 2025 FDA target that is unverified as met and a current status under private ownership that is not publicly traceable. On AI substance the cleared digital-surgery features are machine-vision and digital-laparoscopy assists that are real but incremental rather than autonomy, and the Performance-Guided Surgery framing was oversold relative to what is cleared.

surgicalView model →

Asensus Surgical on the deployment map

Where Asensus Surgical's robots are verified operating. Explore the deployment map by place and type.

Explainers

Plain-language answers to the questions people ask about Asensus Surgical, from DEPLOY’s explainer library. Each is written in the language of the question and cross-checked against this registry.

  • What is a surgical robot?

    A surgical robot is a computer-assisted operative platform that places robotic arms, instruments, and visualization systems between the surgeon and the patient. The 2026 commercial cohort includes Intuitive Surgical (da Vinci + Ion; 11,395 + 1,041 systems installed per SEC 10-Q), Medtronic Hugo, CMR Surgical Versius, Asensus/Karl Storz Senhance, Stereotaxis Genesis, Distalmotion Dexter, Moon Surgical Maestro (ScoPilot is the cohort's genuine shipped surgical AI standout, FDA-cleared with a Predetermined Change Control Plan), and Brain Navi NaoTrac (autonomous registration, not tissue manipulation). J&J Ottava (De Novo submission January 2026) and Vicarious Surgical V1 remain pre-market research per DEPLOY's FDA-clearance-as-gating-event framework. The autonomy spectrum runs from teleoperated baseline through analytics AI to narrow autonomous registration; tissue-manipulation autonomy remains research demos on production hardware, not shipped product.

  • How does DEPLOY track the 2023 Asensus Senhance uncontrolled-arm Class I recall?

    DEPLOY tracks the [2023 Asensus Senhance uncontrolled-arm Class I recall](https://registry.deploy.report/incidents/asensus-senhance-uncontrolled-arm-recall-2023) at primary-source-anchored FDA-recall-database verification depth as a software_defect Class I recall at Asensus Surgical pre-acquisition corporate-state context. The substrate: Class I recall September 15, 2023; software malfunction caused uncontrolled arm motion of the laparoscope instrument actuator, which rotated continuously in one direction after the surgeon disengaged teleoperation (critical-tissue-trauma risk; emergency stop available as mitigation); 5 US devices at exact verification depth; cease-use until software updated to v2.7.5; no patient harm reported; remediated. Root cause: software_defect (software malfunction; laparoscope instrument actuator rotated continuously after teleoperation was disengaged). The incident operates as the CANONICAL worked example for verified-vs-claimed at acquisition-state boundary granularity: 2023 incident occurred at Asensus Surgical pre-acquisition corporate-state; August 22, 2024 Karl Storz acquisition (full_acquisition structure + reported valuation_basis at ~$0.35/share per [the acquisition history Project B methodology pillar](/explainers/how-deploy-tracks-acquisition-history-state)) transitioned Senhance/LUNA product lines to Karl Storz subsidiary corporate-state. Completes the cross-cohort surgical quartet (2026 da Vinci SureForm gray-reload + within-da-Vinci year-discipline + 2021 ROSA ONE Brain wrong-trajectory + 2023 Asensus Senhance uncontrolled-arm) at canonical-reference depth + completes the three-incident software_defect-as-cross-cohort-root-cause-class structural composition (2021 ROSA ONE Brain + 2023 Asensus Senhance + 2024 Stryker Mako). Framework reads incident at primary-source-anchored verification depth across three-axis substrate composition pattern simultaneously: numerator (Class I + software_defect + recall_ordered + remediated) + denominator (5 US devices at exact verification; substantively higher-verification-completeness tier within broader cohort exposure_hours 128-nulls honest-absence) + scalar selectivity (no patient harm reported as substantive editorial state per banked honesty-as-strength editorial framing).

Current leadership (1)

Former / Previously (1)

Safety record

2 recalls on record (2 critical). Most recent: Sep 2023.

critical
2

Most recent: Sep 2023

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Full safety record: incidents, sourcing, and exposure data →

Incidents affecting Asensus Surgical (2)

Includes incidents linked directly to this company, to its models, or to deployments of its models or under its operation. Retracted incidents are excluded from this view but remain reachable at their canonical URLs.

Recent coverage

Asensus Surgical in third-party press

Asensus Senhance surgical robot receives FDA 510(k) clearance

Jan 1, 2024

Karl Storz to fully integrate Asensus, discontinue Senhance

Jan 1, 2024

Peer companies